Print

Orgenesis Enters Into R&D Agreement With the Fraunhofer IGB  
11/12/2012 9:58:01 AM

WHITE PLAINS, N.Y.--(BUSINESS WIRE)--Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning insulin-producing cells as a treatment for diabetes, announced today that it has entered into a service agreement (the “Agreement”) with the Fraunhofer Institute for Interfacial Engineering and Biotechnology (“Fraunhofer IGB”), a leading German contract research and development center for regenerative medicine.
//-->